NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00054-0248-12 | 00054-0248 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 28, 2018 | In Use | |
54868-5005-00 | 54868-5005 | Cyclophosphamide | Cyclophosphamide | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Aug 17, 1999 | In Use | |
60760-0277-10 | 60760-0277 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 2, 2019 | In Use | |
00591-4365-60 | 00591-4365 | Abiraterone acetate | Abiraterone acetate | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Jul 13, 2023 | In Use | |
71205-0421-10 | 71205-0421 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 10, 2020 | In Use | |
71205-0797-10 | 71205-0797 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 3, 2023 | In Use | |
67457-0208-50 | 67457-0208 | Dexrazoxane | Dexrazoxane Hydrochloride | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Nov 18, 2011 | In Use | |||
67457-0311-05 | 67457-0311 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Sep 9, 2019 | In Use | ||
16729-0436-30 | 16729-0436 | Fulvestrant | FULVESTRANT | 250.0 mg/5mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Jan 21, 2021 | In Use | ||
16729-0522-05 | 16729-0522 | Pemetrexed disodium | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sep 8, 2022 | In Use | |
17478-0761-06 | 17478-0761 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Jun 20, 2014 | In Use | |
50881-0013-01 | 50881-0013 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | In Use | |
53217-0255-24 | 53217-0255 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 29, 2001 | In Use | |
53217-0255-27 | 53217-0255 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 29, 2001 | In Use | |
23155-0649-41 | 23155-0649 | CARMUSTINE | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Oct 1, 2019 | In Use | ||
68001-0565-28 | 68001-0565 | Cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Apr 10, 2023 | In Use | |
51655-0933-04 | 51655-0933 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 25, 2022 | In Use | |
71258-0015-02 | 71258-0015 | iobenguane I-131 | Azedra | 15.0 mCi/mL | Chemotherapy | Radiopharmaceutical | I 131 | Intravenous | Jul 30, 2018 | In Use | |
51655-0809-53 | 51655-0809 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 6, 2022 | In Use | |
55150-0383-01 | 55150-0383 | Pemetrexed | Pemetrexed | 1000.0 mg/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
70710-1656-01 | 70710-1656 | Decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 11, 2023 | In Use | |
00069-1014-15 | 00069-1014 | Bosutinib | BOSULIF | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 2, 2024 | In Use | |
00069-1031-30 | 00069-1031 | Talazoparib | Talzenna | 0.1 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jun 21, 2023 | In Use | |
00069-1235-30 | 00069-1235 | Talazoparib | Talzenna | 0.35 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jun 21, 2023 | In Use | |
00409-0181-01 | 00409-0181 | GEMCITABINE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug 26, 2011 | In Use |
Found 11120 results — Export these results